Stockreport

SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results

SAB Biotherapeutics, Inc.  (SABS) 
PDF SIOUX FALLS, S.D., May 16, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy pl [Read more]